PLASMA Act

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R.8528 - PI Post Acute Access Act: This bill allows for separate payment under Medicare to skilled nursing facilities for items and services that are needed to administer intravenous immune globin (IVIG) to patients with primary immune deficiency diseases (rare genetic disorders that impair the immune system and increase vulnerability for other infections). H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

Client expense: $360,000 · Firm income: Not reported

Government targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation H.R 1476 PLASMA Act

Client expense: $380,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate Issues related to the 340B program

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).

Client expense: Not reported · Firm income: $60,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 / S. 694 Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act);Phases in manufacturer discounts for plasma‑derived therapies under the Medicare Part D Manufacturer Discount Program, gradually increasing required discounts over several years to avoid sudden cost impacts on access to plasma‑derived medicines. H.R. 1143 Medicare IVIG Access Enhancement Act of 2025;Expands Medicare coverage for in‑home administration of intravenous immune globulin (IVIG) to include treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy, in addition to primary immune deficiency diseases. H.R. 2343 John W. Walsh Alpha‑1 Home Infusion Act of 2025;Provides Medicare coverage for at‑home augmentation therapy for beneficiaries with emphysema resulting from severe hereditary alpha‑1 antitrypsin (AAT) deficiency when furnished by qualified home infusion therapy suppliers. S. 1818 / H.R. 3546 Prescription Drug Price Relief Act of 2025;Requires HHS to annually review brand‑name drugs for excessive pricing and, when prices exceed specified international benchmarks or reasonableness standards, to void government‑granted exclusivities and facilitate generic or biosimilar competition. S. 1587 / H.R. 3375 Fair Prescription Drug Prices for Americans Act;Establishes an international reference pricing system that caps U.S. retail list prices for certain prescription drugs and biologics at the average price in selected peer countries, with penalties for manufacturers that exceed the cap. S. 1753 End Price Gouging for Medications Act;Requires HHS to set annual reference prices for prescription drugs, generally based on the lowest prices in selected foreign markets, and prohibits retail prices under federal health programs from exceeding those reference prices. Issues related to Most Favored Nations drug pricing proposals (incl. H.R. 7837) Most Favored Patient Act of 2026; Directs the Center for Medicare and Medicaid Innovation to test a model implementing most‑favored‑nation drug pricing, tying Medicare payment rates to lower prices paid in comparable foreign countries. Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation

Client expense: $400,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act Issues related to Most Favored Nations drug pricing proposals Issues related to the implementation of P.L. 117-169, the Inflation Reduction Act; drug price negotiations, Part D rebate

Client expense: $470,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).

Client expense: Not reported · Firm income: $50,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Issues related to Medicare Most Favored Nation

Client expense: $330,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. H.R. 1 (P.L. 119-21), One Big Beautiful Bill Act. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

Issues related to prescription drug value, including implementation of the Inflation Reduction Act (PL 117-169), and implementation of Executive Order 14273, Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients. Issues related to regulation of pharmaceuticals. H.R.1476-Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act).

Client expense: Not reported · Firm income: $40,000

Government targets: Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act; drug price negotiations, Part D rebate

Client expense: $450,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Clarify or reform the 340B program Issues related to patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Issues related to rare disease diagnosis and access to care Issues related to Pharmacy Benefit Managers (PBMs) H.R. 1476, S. 694, PLASMA Act

Client expense: $1,570,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability; Medicare/Medicaid Most Favored Nation

Client expense: $540,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Clarify or reform the 340B program Issues related to patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Issues related to rare disease diagnosis and access to care Issues related to Pharmacy Benefit Managers (PBMs) H.R. 1476, S. 694, PLASMA Act

Client expense: $1,520,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma based therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. H.R. 1, One Big Beautiful Bill Act. Issues related to pharmacy benefit management. Issues related to Most Favored Nation drug pricing.

Client expense: Not reported · Firm income: $50,000

Government targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE

H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 / S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (PLASMA Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program H.R. 1143, Medicare IVIG Access Enhancement Act of 2025 H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025 H.R. 2172, Preserving Patient Access to Home Infusion Act S. 1818 / H.R.3546, Prescription Drug Price Relief Act of 2025 S.1587 / H.R.3375, Fair Prescription Drug Prices for Americans Act S.1753, End Price Gouging for Medications Act H.R. 3493, Global Fairness in Drug Pricing Act

Client expense: $390,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Clarifying or reforming the 340B program Value-based drug contracting Patient access of plasma therapies Global pharmaceutical supply chain operations and manufacturing locations Most Favored Nation/International Reference Pricing Co-pay accumulators maximizers, alternate funding models Customs Border Protection changes impacting southern border plasma collections Promoting the Congressional Plasma Caucus Rare disease diagnosis and access to care Pharmacy Benefit Managers (PBMs) Drug pricing, including House and Senate draft bills H.R. 1476, S. 694, PLASMA Act H.R. 2528, Association Health Plans Act H.R. 2214, DRUG Act

Client expense: $490,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

The PLASMA Act (H.R.1476/S.694): issues related to Part D and plasma-derived therapies.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

Issues related to plasma therapies. H.R. 1476 / S. 694, Preserving Life-saving Access to Specialty Medicines in America (PLASMA) Act. Issues related to gene therapies. Issues related to value-based payments. Issues related to drug shortages. Monitored implementation of P.L. 117-169, the Inflation Reduction Act, as it relates to plasma derived products and drug pricing. Monitored issues related to pharmacy benefit management.

Client expense: Not reported · Firm income: $50,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R.1476/S.694, PLASMA Act

Client expense: Not reported · Firm income: $40,000

Government targets: SENATE

HR 1476--Preserving Life-saving Access to Specialty Medicines in America Act (PLASMA Act)--Medicare Part D phase-in of manufacturer liability

Client expense: $950,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE

H.R. 1476 & S. 694, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343 , John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Client expense: Not reported · Firm income: $80,000

Government targets: HOUSE OF REPRESENTATIVES, SENATE

S. 694 & H.R. 1476, Preserving Life-Saving Access to Specialty Medicines in America Act (Plasma Act), legislation to provide rebate phase-in for plasma-derived therapies under the Medicare Part D program. H.R. 1143, Medicare IVIG Access Enhancement Act of 2025. H.R. 2343, John W. Walsh Alpha-1 Home Infusion Act of 2025. H.R. 2172, Preserving Patient Access to Home Infusion Act. Issues related to the implementation of P.L. 117-169, The Inflation Reduction Act.

Client expense: $360,000 · Firm income: Not reported

Government targets: HOUSE OF REPRESENTATIVES, SENATE